You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Whole-Body In-Vivo Neutron Activation Analysis In Assessing Treatment Of Renal Osteodystrophy With 1-Alpha-Hydroxycholecalciferol
Contributor:
Naik, R. B.;
Gosling, P.;
Price, C. P.;
Robinson, B. H. B.;
Dabek, J. T.;
Heath, D. A.;
James, H. M.;
Kanis, J. A.;
Smith, R.
imprint:
British Medical Association, 1976
Published in:The British Medical Journal
Language:
English
ISSN:
0007-1447
Origination:
Footnote:
Description:
<p>Four selected adults with different patterns of osteodystrophy receiving regular dialysis were treated with /// 1-α-hydroxycholecalciferol (1-α-OHD₃) 0·5-2 μg/day for 10 to 12 months. In two patients, one with osteitis fibrosa and the other with osteomalacia, significant biochemical, radiological, and histological improvements occurred, and total body calcium measured by in-vivo neutron activation analysis increased. In two patients, in whom there were no increases of whole-body calcium, neither biochemical improvement nor healing of bone lesions occurred during the study; in one of these patients the effect of 1-α-OHD₃ on bone resorption may have contributed to loss of body calcium and deterioration of bone disease. 1-α-OHD₃ may therefore be a valuable adjunct in the treatment of only some patients with renal osteodystrophy. Whole-body in-vivo neutron activation seems to provide a sensitive and non-invasive index of early response to treatment.</p>